13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
39 檔
29.5%
In Q4 2025, Atle Fund Management AB's U.S. equity holdings reached a combined market value of $371.7M, distributed across 39 disclosed stock positions.
Atle Fund Management AB executed strategic sector rebalancing during Q4 2025, establishing 8 new positions while fully exiting 7 holdings and trimming 12 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 10.67% | +0.95% | -16.41% | |
| 2 | ABBV | Abbvie Inc | Stock-Healthcare | 7.89% | +1.00% | +17.45% | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 6.57% | -0.85% | +21.66% | |
| 4 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 5.53% | -0.91% | +10.20% | |
| 5 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.29% | +0.77% | -7.63% | |
| 6 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.03% | -0.41% | +13.27% | |
| 7 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.92% | -1.22% | +33.29% | |
| 8 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.45% | -1.34% | -19.13% | |
| 9 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 3.32% | -1.05% | +29.37% | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.31% | -1.18% | +25.38% | |
| 11 | SYK | Stryker CORP | Stock-Healthcare | 3.01% | -0.53% | +17.86% | |
| 12 | CVS | Cvs Health CORP | Stock-Healthcare | 2.70% | +1.08% | — | |
| 13 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.66% | +0.21% | -19.76% | |
| 14 | COR | Cencora Inc | Stock-Healthcare | 2.56% | +0.24% | -16.90% | |
| 15 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.33% | -0.10% | — | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.29% | +0.75% | +5.66% | |
| 17 | AMGN | Amgen Inc | Stock-Healthcare | 2.29% | -2.81% | EXIT | |
| 18 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.26% | +0.15% | -4.19% | |
| 19 | INCY | Incyte CORP | Stock-Healthcare | 2.23% | -0.83% | — | |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.21% | +0.49% | +1.76% | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 2.16% | +0.35% | -4.11% | |
| 22 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.13% | -0.29% | +25.30% | |
| 23 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.99% | -0.74% | -35.02% | |
| 24 | UFPT | Ufp Technologies Inc | Stock-Other | 1.63% | — | — | |
| 25 | INSM | Insmed Inc | Stock-Healthcare | 1.55% | -0.25% | — | |
| 26 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.54% | -0.03% | -22.53% | |
| 27 | ABVX | Abivax Sa-adr | Stock-Other | 1.36% | +0.55% | — | |
| 28 | CELC | Celcuity Inc | Stock-Other | 1.33% | -0.72% | +12.58% | |
| 29 | IRON | Disc Medicine Inc | Stock-Other | 1.22% | -0.17% | +4.98% | |
| 30 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.07% | -0.35% | — | |
| 31 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.02% | -0.90% | EXIT | |
| 32 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.00% | -0.37% | — | |
| 33 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.93% | -0.71% | EXIT | |
| 34 | ACLXGBX | Arcellx Inc | Stock-Other | 0.87% | — | +62.12% | |
| 35 | DXCM | Dexcom Inc | Stock-Healthcare | 0.84% | +0.45% | -21.92% | |
| 36 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.74% | — | — | |
| 37 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.60% | +0.41% | -45.34% | |
| 38 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.28% | — | -38.91% | |
| 39 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.23% | +0.26% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRK | Merck & Co. Inc. | +1.3% | +21.66% | Add |
| 2 | AMGN | Amgen Inc | +0.8% | +58.65% | Add |
| 3 | RVMD | Revolution Medicines Inc | +0.7% | +5.66% | Add |
| 4 | CELC | Celcuity Inc | +0.6% | +12.58% | Add |
| 5 | VRTX | Vertex Pharmaceuticals Inc | +0.6% | +29.37% | Add |
| 6 | ISRG | Intuitive Surgical Inc | +0.6% | +13.27% | Add |
| 7 | TMO | Thermo Fisher Scientific Inc | +0.4% | +10.20% | Add |
| 8 | IRTC | Irhythm Holdings Inc | +0.1% | +25.30% | Add |
| 9 | NAMS | NewAmsterdam Pharma Company N.V. | 0% | +1.76% | Add |
| 10 | ACLXGBX | Arcellx Inc | 0% | +62.12% | Add |
| 11 | IRON | Disc Medicine Inc | 0% | +4.98% | Add |
| 12 | AUTL | Autolus Therapeutics PLC | 0% | — | Unchanged |
| 13 | BSX | Boston Scientific CORP | 0% | +25.38% | Add |
| 14 | UNH | Unitedhealth Group Inc | -0.1% | +6.62% | Add |
| 15 | BBIO | Bridgebio Pharma Inc | -0.1% | -19.13% | Trim |
| 16 | ONC | Beone Medicines Ltd-adr | -0.2% | +33.29% | Add |
| 17 | UFPT | Ufp Technologies Inc | -0.2% | — | Unchanged |
| 18 | KRYS | Krystal Biotech Inc | -0.3% | -19.76% | Trim |
| 19 | SYK | Stryker CORP | -0.3% | +17.86% | Add |
| 20 | CAH | Cardinal Health Inc | -0.3% | -22.53% | Trim |
| 21 | MIRM | Mirum Pharmaceuticals Inc | -0.4% | -4.19% | Trim |
| 22 | ABBV | Abbvie Inc | -0.5% | +17.45% | Add |
| 23 | DXCM | Dexcom Inc | -0.5% | -21.92% | Trim |
| 24 | LLY | Eli Lilly & Co | -0.5% | -16.41% | Trim |
| 25 | CRBP | Corbus Pharmaceuticals Holdi | -0.6% | -38.91% | Trim |
| 26 | SLNOEUR | Soleno Therapeutics Inc | -0.7% | +4.29% | Add |
| 27 | BCAX | Bicara Therapeutics Inc | -0.7% | -45.34% | Trim |
| 28 | ALKS | Alkermes plc | -0.8% | -4.11% | Trim |
| 29 | COR | Cencora Inc | -1% | -16.90% | Trim |
| 30 | NBIX | Neurocrine Biosciences Inc | -1.4% | -7.63% | Trim |
| 31 | GILD | Gilead Sciences Inc | -1.4% | -35.02% | Trim |
| 32 | CVS | Cvs Health CORP | — | NEW | New buy |
| 33 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 34 | INCY | Incyte CORP | — | NEW | New buy |
| 35 | INSM | Insmed Inc | — | NEW | New buy |
| 36 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 37 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
| 38 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 39 | PYXS | Pyxis Oncology Inc | — | NEW | New buy |
| 40 | EW | Edwards Lifesciences CORP | — | EXIT | Sold out |
| 41 | ✓ | Merus N V | — | EXIT | Sold out |
| 42 | HRMY | Harmony Biosciences Holdings | — | EXIT | Sold out |
| 43 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 44 | SMMT | Summit Therapeutics Inc | — | EXIT | Sold out |
| 45 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 46 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 39 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ABBV, MRK) accounted for 29.5% of total reported equity market value during Q4 2025.
Top New Position Initiated
CVS
市值: $8.5M
Top Position Liquidated / Trimmed
EW
前期市值: $542.1K
During Q4 2025, Atle Fund Management AB's top holdings by market value included LLY (10.7%)、ABBV (7.9%)、MRK (6.6%). The largest single position, LLY, represented 10.7% of total portfolio value.
In Q4 2025, Atle Fund Management AB made 44 total portfolio adjustments, initiating 8 new buys, adding to 17 positions, trimming 12 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.